IBRX ImmunityBio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IBRX

Price (delayed)

$5.6

Market cap

$3.87B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.09

Enterprise value

$4.63B

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer ...

Highlights
ImmunityBio's EPS has increased by 5% QoQ but it has decreased by 2.8% YoY
ImmunityBio's revenue has shrunk by 51% QoQ and by 48% YoY
The company's gross profit has shrunk by 51% QoQ and by 48% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://www.nantkwest.com/
Peers: OMGA ONCT

Key stats

What are the main financial stats of IBRX
Market
Shares outstanding
691.57M
Market cap
$3.87B
Enterprise value
$4.63B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
12,476.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15,346.12
Earnings
Revenue
$302,000
EBIT
-$464.13M
EBITDA
-$439.89M
Free cash flow
-$412.85M
Per share
EPS
-$1.09
Free cash flow per share
-$0.61
Book value per share
-$1.03
Revenue per share
$0
TBVPS
$0.57
Balance sheet
Total assets
$400.68M
Total liabilities
$1.09B
Debt
$894.78M
Equity
-$692.01M
Working capital
$141.96M
Liquidity
Debt to equity
-1.29
Current ratio
3.64
Quick ratio
3.21
Net debt/EBITDA
-1.73
Margins
EBITDA margin
-145,657.6%
Gross margin
100%
Net margin
-198,994%
Operating margin
-114,525.2%
Efficiency
Return on assets
-147.6%
Return on equity
N/A
Return on invested capital
-54%
Return on capital employed
-133.8%
Return on sales
-153,686.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IBRX stock price

How has the ImmunityBio stock price performed over time
Intraday
2%
1 week
-3.28%
1 month
-17.28%
1 year
129.51%
YTD
11.55%
QTD
-11.39%

Financial performance

How have ImmunityBio's revenue and profit performed over time
Revenue
$302,000
Gross profit
$302,000
Operating income
-$345.87M
Net income
-$600.96M
Gross margin
100%
Net margin
-198,994%
The net margin has dropped by 171% year-on-year and by 112% since the previous quarter
ImmunityBio's operating margin has plunged by 97% from the previous quarter and by 83% YoY
ImmunityBio's revenue has shrunk by 51% QoQ and by 48% YoY
The company's gross profit has shrunk by 51% QoQ and by 48% YoY

Growth

What is ImmunityBio's growth rate over time

Valuation

What is ImmunityBio stock price valuation
P/E
N/A
P/B
N/A
P/S
12,476.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15,346.12
ImmunityBio's EPS has increased by 5% QoQ but it has decreased by 2.8% YoY
ImmunityBio's equity has decreased by 31% YoY and by 18% QoQ
The P/S is 150% more than the 5-year quarterly average of 4883.5 and 149% more than the last 4 quarters average of 4909.5
ImmunityBio's revenue has shrunk by 51% QoQ and by 48% YoY

Efficiency

How efficient is ImmunityBio business performance
ImmunityBio's return on sales has shrunk by 161% YoY and by 111% QoQ
IBRX's return on assets is down by 18% year-on-year
The company's return on invested capital rose by 17% QoQ and by 10% YoY

Dividends

What is IBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IBRX.

Financial health

How did ImmunityBio financials performed over time
The total assets is 63% less than the total liabilities
ImmunityBio's quick ratio has decreased by 30% from the previous quarter
The current ratio has decreased by 28% from the previous quarter
ImmunityBio's equity has decreased by 31% YoY and by 18% QoQ
The debt rose by 17% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.